The performance of traditional Chinese medicine has maintained good growth, and the advantages of exclusive varieties are expected to be further highlighted

【Pharmaceutical Network Market Analysis】 As of August 29, 342 of the A-share pharmaceutical companies disclosed their 2022 semi-annual reports, and more than half of them achieved year-on-year growth
in net profit attributable to the mother of pharmaceutical companies.

From the perspective of segmentation, the performance of traditional Chinese medicine consumer goods and exclusive varieties of traditional Chinese medicines maintained good growth
.

It is reported that in the traditional Chinese medicine industry, the net profit attributable to the mother of longshen Rongfa, Guangyuyuan, Dong'e Ejiao and Jiaying Pharmaceutical has increased by more than 100% year-on-year, and the net profit attributable to the mother of Baiyun Mountain, China Resources Sanjiu, Katazai Zhen, Yiling Pharmaceutical and Jichuan Pharmaceutical has ranked first, all of which exceed 1 billion yuan
.

Among them, Longshen Rongfa achieved operating income in the first half of the year by 39.
65% year-on-year to 150 million yuan, and net profit increased by 568.
10% year-on-year to 1.
961 million yuan
.

Long Shenrong said that the company through strengthening the construction of the marketing team, optimizing business integration, actively develop the market, intensive cultivation, drug sales revenue to achieve year-on-year growth
.

Among them, Longshenrong Fa Drop Pill Products achieved an increase in operating income of 64.
28% year-on-year to 101 million yuan, and the gross profit margin increased by 12.
98 percentage points year-on-year
.

In the first half of this year, Guangyuyuan achieved revenue increased by 27.
71% year-on-year to 479 million yuan; realized net profit increased by 112.
65% year-on-year to 6.
6683 million yuan; and realized net profit attributable to shareholders of listed companies increased by 116.
27% year-on-year to 7.
8254 million yuan
.

It is reported that in the first half of the year, the reputation of the long-distance review of the situation to optimize the development strategy, and actively carry out the "100 days to clear arrears", "cost reduction and efficiency increase" and "incremental expansion" special actions, adhere to the strengthening of the core business, optimize the product structure, achieve the overall business benign growth, enterprise growth logic further strengthened
.

In the first half of this year, Dong'e Ejiao achieved an increase of 8.
25% in operating income to 1.
826 billion yuan, and a net profit attributable to shareholders of listed companies increased by 106% year-on-year to 308 million yuan
.

During the reporting period, the operating income of the pharmaceutical industry business segment of Dong'e Ejiao increased by 10.
2% year-on-year to 1.
732 billion yuan, accounting for 94.
85% of the operating income, an increase of 1.
68 percentage points
over the same period of the previous year.

Among them, ejiao and series products achieved revenue increased by 9.
72% year-on-year to 1.
594 billion yuan, continuing the momentum of growth and driving the company's revenue to achieve year-on-year growth
.

It is understood that since the listing of East Ejiao, the core product ejiao block demand is strong, and the price has continued to increase, driving the company's performance to grow rapidly
.

Jiaying Pharmaceutical achieved a net profit attributable to shareholders of listed companies in the first half of this year, an increase of 105.
33% year-on-year to 8.
5947 million yuan; Net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, increased by 111.
59% year-on-year to RMB8.
8041 million
.

Jiaying Pharmaceutical said that during the reporting period, the company closely focused on the company's annual work plan, opened a new journey to promote the company's high-quality development, the company's operations generally maintained stable and healthy development, production work was carried out steadily, and marketing was promoted
in an orderly manner.

The company has completed the annual operating indicators
well.

Baiyun Mountain achieved an operating income of 37.
220 billion yuan (RMB, the same below) in the first half of this year, an increase of 3.
02%
year-on-year.

Net profit attributable to shareholders of the company was 2.
590 billion yuan, an increase of 3.
50%
year-on-year.

It is reported that Baiyun Mountain adheres to the deep ploughing and meticulous cultivation, and does the business
of the fine and large southern medicine plate.

During the reporting period, the Great Southern Pharmaceutical Sector seized the opportunity to open up the market and actively promoted the adjustment of the marketing model; Vigorously promote the concept of "fashion Chinese medicine", and promote the rapid growth of a number of key varieties by focusing on resources to create superstar varieties in various fields and tapping the potential of second-tier echelon products; Continue to enhance the brand influence of Baiyun Mountain, actively promote the revitalization project of the group, and continuously enhance the popularity and recognition of
brands and products.

Crs 39 achieved operating income of 8.
401 billion yuan in the first half of this year, an increase of 6.
82% year-on-year; Attributable net profit was 1.
433 billion yuan, an increase of 4.
16%
year-on-year.

China Resources Sanjiu said that the company's overall operating performance in the first half of the year was good, mainly due to the growth of CHC business, especially the rapid growth of professional brands, big health and other businesses
.

It is expected that the company's operating income will achieve double-digit growth in 2022, and net profit will strive to match the level of
revenue growth.

In the first half of this year, Katazai achieved revenue of 4.
423 billion yuan, an increase of 14.
91% year-on-year, net profit attributable to the mother of 1.
314 billion yuan, an increase of 17.
85% year-on-year, and net profit of 1.
317 billion yuan, an increase of 18.
08%
year-on-year.

It is reported that the series of tablets has grown steadily, and Angong Niuhuang Pill has achieved rapid release
.

In the first half of 2022, the company's liver disease drugs (tablets and epilepsy series) achieved revenue of 1.
97 billion yuan, an increase of 15.
32% year-on-year, cardiovascular and cerebrovascular drugs (Angong Niuhuang Pills, etc.
) achieved revenue of 123 million yuan, an increase of 171% year-on-year, the pharmaceutical circulation sector achieved revenue of 1.
873 billion yuan, an increase of 17.
42% year-on-year, and the daily chemical plate achieved revenue of 350 million yuan, down 19.
08% year-on-year.
The food sector achieved revenue of 73 million yuan, an increase of 311.
02%
year-on-year.

In the first half of this year, Yiling Pharmaceutical achieved operating income of 5.
566 billion yuan and net profit attributable to shareholders of listed companies of 1.
049 billion yuan, an increase of 8.
76% year-on-year; Achieved a net profit attributable to the shareholders of the listed company, net of non-recurring gains and losses, of 1.
050 billion yuan, an increase of 13.
04%
year-on-year.

It is reported that during the reporting period, Yiling Pharmaceutical continued to strive to expand the international market, actively promoted the registration and export of products in overseas markets, and continuously promoted the implementation
of the company's comprehensive internationalization strategy.

In the first half of 2022, Lianhua Qingyi capsules were approved for registration and listing in Liberia and Nigeria, which had a positive impact on
the company's expansion of overseas markets.

In the first half of this year, Jichuan Pharmaceutical achieved revenue of 3.
863 billion yuan, an increase of 4.
92% year-on-year; Net profit attributable to the mother was 1.
016 billion yuan, an increase of 18.
94% year-on-year; Deduct non-net profit of 900 million yuan, an increase of 11.
88%
year-on-year.

Jichuan Pharmaceutical said that during the reporting period, Jichuan Pharmaceutical steadily carried out various business work, the company's business as a whole remained stable, and its operating income and net profit increased
compared with the same period last year.

It is understood that under the policy dividend, the Chinese medicine industry is ushering in a golden age
of rapid development.

According to relevant data, the TCM health industry chain is developing at a high speed, and it is expected to reach 2,973 billion yuan
in 2030.

In this context, Chinese medicine enterprises will also usher in more opportunities
.

In addition, some institutions believe that with the advancement of the collection of proprietary Chinese medicines and the negotiation of medical insurance, the impact of factors such as the superimposed epidemic situation, the differentiation of the Chinese medicine industry will be further intensified, and the advantages of exclusive varieties are expected to be further highlighted
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.